Success imaging in microPET and microSPECT with radiopharmaceuticals to Alzheimer’s disease

1765 Objectives Alzheimer’s disease (AD) is one of the epidemic neurodegenerative disorder-affecting millions of elders. Numbers of dystrophic neuritis has correlated with severity of dementia been associated with fibrillar b-amyloid. Senile plaques (SPs) and neurofibrillay tangles (NFTs) are hallmarks in AD, histological dye analogs biomarker for mapping Ab, like [18F]FDDNP and [123I]IMPY, showed the superiority characteristics. Methods Synthesis protocol of [18F]FDDNP and [123I]IMPY were apply on auto-synthesizer. In vivo study were used transgenic mice (Tg2576) for the assay. In study, take those mice (post-injected for 30min) for microPET or microSPECT for imaging. Results High quality of Radiochemical (purity >95%) were synthesized. In vivo imaging, microPET or microSPECT showed that Tg2576 brain section/reference (cerebellum or muscle) ratio lager than control mice (0.83 to 1.00 and 0.05 to 0.19 between Tg2576 and control mice in FDDNP; 2.8, 2.9 and 1.5, 1.4 fold between frontal cortex and thalamus to cerebellum in IMPY). Conclusions In the report, synthesize [18F]FDDNP and [123I]IMPY on auto-synthesizer and estimate in vivo assay by transgenic mice (Tg2576). Superiority result in tracing beta-amyloid plaques in nuclear medicine modality. In the past, researcher less the imaging report by transgenic mice. In the study had encourage result by this kind of radiopharmaceuticals wish to exploitative the preclinical platform for early diagnosis on AD patients